Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin effects in diabetic patients with coronary artery disease
IRCT20190412043247N2Phase 4Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial in type 2 diabetes mellitus (T2DM) and coronary arteriosclerosis comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Changes in plasma interleukin 6. Started Jun 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20190412043247N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190412043247N2.